Drugs Made In America Acquisition (DMAA) Common Equity (2024 - 2025)
Drugs Made In America Acquisition's (DMAA) quarterly Common Equity came in at -$7.3 million in Q4 2025, down 2866.77% YoY from $262544.0 in Q4 2024, and down 1293.12% on a QoQ basis from $608822.0 in Q3 2025.
Drugs Made In America Acquisition (DMAA) Common Equity (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAA) has 2 years of Common Equity data on file, last reported at -$7.3 million in Q4 2025.
- Quarterly Common Equity fell 2866.77% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.3 million (down 2866.77% YoY) and the FY2025 annual result came in at -$7.3 million, down 2866.77% from the prior year.
- Common Equity eased to -$7.3 million in Q4 2025, from $608822.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $608822.0 in Q3 2025 to a low of -$7.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oxley Bridge Acquisition | 585.76 Mn | 585.76 Mn | - | -11.21 Mn |
| 2 | Launch Two Acquisition | 557.86 Mn | 557.86 Mn | - | -10.94 Mn |
| 3 | Drugs Made In America Acquisition | 506.00 Mn | 506.00 Mn | - | -17.93 Mn |
| 4 | Cantor Equity Partners IV | 468.00 Mn | 468.00 Mn | - | -170,609.00 |
| 5 | GP-Act III Acquisition | 401.06 Mn | 401.06 Mn | - | -16.30 Mn |
| 6 | Aldel Financial | 397.49 Mn | 397.49 Mn | - | 316,106.00 |
| 7 | Pioneer Acquisition I | 390.89 Mn | 653.32 Mn | - | -11.79 Mn |
| 8 | Republic Digital Acquisition | 389.25 Mn | 388.51 Mn | - | -11.91 Mn |
| 9 | Gores Holdings X | 385.06 Mn | 384.87 Mn | - | -31.02 Mn |
| 10 | Drugs Made In America Acquisition | 215.62 Mn | 215.62 Mn | - | -7.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | 608,822.00 |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.18 Mn |
| Dec 31, 2024 | -244,845.00 |